From October 17 to 21, 2025, in Berlin, Germany, the European Society for Medical Oncology (ESMO) Congress will be held. Several major pharmaceutical companies will show off new data from their oncology pipelines. Roche, Eli Lilly, AbbVie, and Gilead/Kite have all made announcements about new treatments for different types of cancer. These treatments include targeted therapies, antibody-drug conjugates, and cell therapy.
Roche will present a large amount of research, with more than 30 abstracts on more than 10 types of cancer. A major presentation at the Presidential Symposium will focus on new data about Tecentriq (atezolizumab) and its use in ctDNA-guided adjuvant treatment for muscle-invasive bladder cancer. The company will also show the final overall survival data from the important ALEX study of Alecensa (alectinib) in non-small cell lung cancer (NSCLC) that is ALK-positive. There will also be information shared about giredestrant, an oral selective oestrogen receptor degrader, in advanced breast cancer that is ER-positive and HER2-negative.
Read More: Gilead Provides Clinical Update on Investigational HIV-1 Treatments GS-1720 and GS-4182
Eli Lilly and Company will share new clinical data for Verzenio (abemaciclib) and other programs that are in development. The main overall survival analysis from the Phase 3 monarchE study of Verzenio in hormone receptor-positive (HR+), HER2-negative, node-positive, high-risk early breast cancer will be presented orally at the end of the day. Lilly will also show data on how well olomorasib, a KRAS G12C inhibitor, works in the brain in people with KRAS G12C-mutant NSCLC and active, untreated brain metastases.
AbbVie will present new data from its antibody-drug conjugate (ADC) platform, which will help it stay ahead in developing targeted therapies for solid tumours. The company will give three talks about Temab-A, a new investigational c-Met directed ADC for advanced solid tumours. AbbVie will also show a new analysis from a Phase 1 study of ABBV-706, a SEZ6-directed ADC, in small cell lung cancer that has come back or is resistant to treatment.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
More than 20 abstracts will be presented by Gilead and Kite, including late-breaking information from the Phase 3 ASCENT-04/KEYNOTE-D19 study of Trodelvy (sacituzumab govitecan-hziy) in combination with Keytruda in first-line PD-L1+ metastatic triple-negative breast cancer. Additionally, Kite and Arcellx will share the most recent results from the Phase 2 iMMagine-1 study of anitocabtagene-autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma.
Last Modified:
Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
